Abstract Purpose: Cyclooxygenase-2 inhibitor (celecoxib, Pfizer) is a promising chemopreventive agent, yet its long-term use may be limited due to increased cardiovascular toxicity.This study was aimed to identify genes and pathways involved in colorectal tumorigenesis and affected by celecoxib. Experimental Design: Normal rat enterocytes (IEC18 cells) and their Ras-transformed derivatives (R1) were exposed for 72 h or over 6 months to celecoxib and analyzed for gene expression pattern using Genechip (RG-U34). Cluster and pathway analyses were done using GeneSpring software and Gene Ontology database. Cyclin D1 was overexpressed in IEC18 cells using stable transfection; cell cycle and prostaglandin synthesis were assessed. Results: Five hundred thirty-eight genes were differentially expressed after transformation, and 70 and 126 genes, respectively, were affected by short and long treatments with celecoxib. Clusters of expression showed different expression in the transformed cells that revert to normal after treatment; they included Ras/Erk/Ral-B, Jagged2/Notch, calcineurin, lysyl-oxidase, etc. Cyclin D1 is up-regulated under the Ras pathway and is down-regulated by celecoxib. Thus, we showed that cyclin D1^transformed cells are resistant to inhibition by celecoxib. Celecoxib was also shown to work via cyclooxygenase-2 inhibition in transformed cells. Conclusions: Celecoxib selectively affects transformed and not normal enterocytes by targeting genes and pathways that are involved in the transformation. Thus, an alternative mechanism is proposed for the cancer-preventive role of celecoxib other than the classic mechanism of inhibiting prostaglandin synthesis, stressing mainly the role of cyclin D1. These data may help in the development of safer and more effective preventive drugs.
Colorectal cancer, the second most prevalent cancer in the developed world and the third most prevalent in developing nations (1) , is responsible worldwide for more than a million new cases of cancer and half a million deaths annually (2) . Colorectal cancer develops through a stepwise process that involves a variety of genetic and epigenetic changes that are acquired over several years and culminate, eventually, in the transformation of normal epithelium into neoplasm (3, 4) . The long latency period thus provides a window of opportunities for preventive therapy, which has become a cornerstone in the modern concept of health.
Up-regulation of cyclooxygenase-2 (COX-2) occurs in 40% to 50% of colorectal adenomatous polyps and in up to 85% of carcinomas (5) . The lack of COX-2 expression in normal colonic mucosa, along with its increased expression in malignant tissue, rationalizes the significant and selective action of COX-2 inhibitors in both the primary and secondary preventions of colorectal cancer. The association between nonsteroidal anti-inflammatory drugs (NSAID) and colorectal neoplasia has thus been studied extensively. Works by Arber et al. (6) and Bertagnolli et al. (7) have recently shown the effectiveness of the selective COX-2 inhibitor, celecoxib, in preventing adenoma formation in the colorectal mucosa. Its long-term use may be limited due to increased cardiovascular system toxicity as, overall, three large-scale clinical studies found a hazard ratio of 1.9 for cardiovascular events (8) .
This study was aimed to find genes and pathways that are unique to malignant transformed cells and are involved in the chemopreventive action of NSAIDs, as former studies teaches that a wide range of mechanisms are targeted by these family of drugs. Cellular proliferation in the colonic mucosa may be directly influenced by NSAIDs (9) by down-regulating prostaglandin E 2 (PGE 2 ) synthesis, a mechanism that diverts the arachidonic acid cascade into lipoxygenase metabolites by inhibiting COX enzymes (10) . Programmed cell death, apoptosis, is another putative target for NSAIDs, as shown in cell culture and animal studies (11 -16) . We seek to elucidate the importance of these and novel alternative pathways for NSAIDs in chemoprevention.
Microarray technology for gene expression profiling was successfully used in the past to pin down genes that can be useful as targets for new treatment modalities and to predict the response of the individual patient to chemotherapy (17, 18) . Two in vitro studies tested for the effect of non-COX2 -specific NSAIDs on colorectal cancer cell lines detecting 130 and 140 genes that alter in sensitive cell lines but not in a resistant cell line to sulindac and aspirin, respectively (19, 20) . In this study, we applied this method to analyze the mechanism of action of celecoxib in a unique in vitro model developed in our laboratory. The model consists of normal, although immortalized, rat enterocytes (IEC18 cells) and Ras-transformed IEC18 cells (R1; refs. 21-24); these cells do not go through cell senescence, yet provide the closest model for normal enterocytes grown in culture. The IEC18 cells have a near diploid karyotype, without mutations in ras, APC, or p53. Moreover, they are contact inhibited; they do not grow in soft agar; their plating efficiency is zero; and they do not produce tumors when injected s.c. into nude mice. The transformed cells proliferate faster, form colonies in soft agar, and have higher saturation density and plating efficiency. Most importantly, they form tumors when injected s.c. into nude mice.
Cyclin D1 is already a well-established oncogene. It functions as an important modulator of cell cycle, overexpressed during the G 1 (25, 26) . Expression of cyclin D1 stimulates DNA synthesis, accelerates cell proliferation, and can by itself lead to a malignant transformation of enterocytes (27) . Overexpression of cyclin D1 is an early event at the carcinogenesis of the gut and elevated nuclear expression levels of cyclin D1 were also found in 67% of esophageal cancers (both squamous cell and adenocarcinomas; refs. 28, 29) , 48% of gastric tumors (28) , 35% of pancreatic adenocarcinomas (30) , and 43% of small (31) and 30% of large bowel (32) tumors, respectively.
In recent preliminary studies, we found that celecoxib inhibited cell growth and induced apoptosis in a time-and dose-dependent manner, whereas rofecoxib did not inhibit cell growth at all (22) . With those cell lines, we carried out gene expression profiling [using Affymetrix rat (RG-U34) Genechip] after short (72 h) and long (6 months) durations of treatment with celecoxib, looking for a differential gene expression profile in the transformed enterocytes compared with the normal cell line, which revert to normal after exposure to the drug.
Materials and Methods
Cell cultures. IEC18 and IEC18-ras (R1) cells were maintained in complete medium, DMEM, and were supplemented with 5% FCS, 1% glutamine, and 1% antibiotics (Bet-Ha'Emek). R1 cells were produced by cotransfection with the drug resistance selectable marker tk-neo and the plasmid pMIKcys, which encodes a mini -human c-K-ras gene (15 kb) that contains a cysteine mutation at codon 12 (24) . To evaluate the patterns of gene expression in celecoxib-sensitive and celecoxibresistant enterocytes, the IEC18 and R1 derivatives were established from parent cells: Sensitive cells are cells that were treated with celecoxib (20 Amol/L) for 72 h. Resistant cells were prepared by exposing the cells to gradually increasing concentrations of celecoxib, 10% increase every four passages, starting at a concentration equal to IC 20 . After 6 months, IEC18-and R1-resistant cells could tolerate 30 and 17 Amol/L of celecoxib, respectively.
Preparation of labeled RNA. Total RNA was extracted from these cells while being active in mitosis, in 70% confluence using Tri Reagent (Sigma-Aldrich). The quality and amount of total RNA were analyzed both by using an agarose gel and a spectrophotometer. The RNA was then used as a template for double-stranded cDNA synthesis with an oligo-(dT)24 primer containing a T7 RNA polymerase promoter site added to the 3 ¶ end (Genset). The cDNA was extracted with phenol/ chloroform, ethanol precipitated, and used as a template for in vitro Fig. 1 . Nonsupervised analysis using 3,242 genes that were present in at least three of the six samples carried out by GeneSpring software. A, Ras-transformed cells were clustered separately from nontransformed cells: The three left signs at the bottom stand for all three samples consisting of IEC18 cells and the three right for those consisting of R1, Ras-transformed cells. B, samples were not clustered according to their treatment status: First and fourth signs stand for the two samples of RNA produced from cells that were not exposed to celecoxib, the second and sixth signs for resistant cells that were treated with the drug for at least 6 mo as indicated, and the third and fifth for short exposure to celecoxib (72 h) as indicated.
transcription (Ambion T7 Megascript system) with biotin-labeled nucleotides (Enzo Diagnostics). Labeled cRNA was fragmented and a hybridization mix was generated as recommended (Affymetrix, Inc.).
Hybridization of microarrays. Aliquots of each sample (10 Ag cRNA in 200 mL hybridization mix) were hybridized to a rat (RG-U34) Genechip (Affymetrix). After hybridization, each array was washed, stained with streptavidin phycoerythrin (Molecular Probes), washed again, hybridized with biotin-labeled anti -streptavidin phycoerythrin antibodies, restained with streptavidin phycoerythrin (Molecular Probes), and scanned.
Analysis of the Genechip data. The algorithm, implanted in Affymetrix Suite Version 5.0 (MAS5), generates signal value (which designates a relative measure of the abundance of the transcript), a detection P value (which indicates the reliability of the transcript detection call), and detection call (present, absent, or marginal). The detection calls were calculated based on detection P value as follows: probe sets with P > 0.06 were designated as absent, 0.06 > P > 0.04 as marginal, and P < 0.04 as present. For interarray comparisons, the data from each array was scaled using MAS5. The mean intensity for each array was corrected by a scaling factor to a set target intensity of 150.
The bioinformatics analysis was carried out using GeneSpring version7 software (Silicon Genetics).
For the normalization procedure, values below 0.01 were set to 0.01. Each measurement was divided by the 50th percentile of all measurements in that sample (per chip normalization). Each gene was divided by the median of its measurements in all samples (per gene normalization). For filtering, genes that had a ''present'' detection call in at least three of six samples were chosen, with 3,242 left for further analysis.
Annotation analysis. NetAffex database was used to extract relevant probe sets according to annotation demands. Functional classification in Gene Ontology of list of genes that discriminates subclasses of samples was examined to find annotation categories that are overrepresented compared with the representation in the array. Annotation analysis was preformed using ''David''.
1 This is an online database hosting tools for annotation analysis, among them the EASE software application. EASE provides statistical methods for discovering enriched biological themes within gene lists using this; we used Fisher's exact probability to choose categories that were significantly overrepresented (P < 0.05).
Construction and transfection of the cyclin D1 expression plasmid. The 1.1-kb human cyclin D1 cDNA containing the entire coding sequence was subcloned into the expression vector pMV7 as was previously described (27) . The resulting plasmid contained a Moloney murine leukemia virus 5 ¶ long terminal repeat and carried neomycin as a selectable marker and a 3 ¶ Moloney murine leukemia virus long terminal repeat. The vector was transfected into IEC18 cells using LipofectAMINE (Invitrogen), and resistant cells were selected in complete medium with 0.2 mg/mL G418 for 3 weeks. Drug-resistant (neo+) clones were isolated (designated D1-D10). Three clones (D1-D3) were chosen for further expansion because they expressed high levels of cyclin D1 (27) as shown in Western blot analysis (done as described ref. 27); clone D1 was chosen for analysis in this study.
Assays for growth inhibition. Cells were plated at a density of 7 Â 10 6 / 10-cm dish in complete medium. The next day, the medium was replaced with a complete medium containing celecoxib (Pfizer), dissolved in DMSO, at the indicated concentrations for 72 h. The adherent and nonadherent cells were collected, during exponential growth of the cells, and counted. Then, 1 Â 10 6 to 2 Â 10 6 cells were washed in PBS, and the pellet was fixed in 3 mL of ethanol for 1 h at 4jC. Cells were pelleted and resuspended in 1 mL PBS and incubated for 30 min with 0.64 mg/mL RNase at 37jC. Cells were stained with 45 Ag/mL propidium iodide, at least 1 h before analysis, by flow cytometry using a standard protocol for cell cycle distribution and cell size (27, 33) . All experiments were repeated thrice with similar results. Data acquisition was done on a FACScan and analyzed using CellQuest software (Becton Dickinson Immunocytometry Systems). Debris was eliminated from the analysis by using a forward-angle light scatter threshold.
Measurement of PGE 2 concentration. IEC18, R1, and D1 cell lines were treated for 72 h with 10 and 20Amol/L of celecoxib. PGE 2 concentration in the medium, as released by the cells, was determined by a commercially available PGE 2 -specific enzyme-linked immunoassay (R&D Biosystems) according to the protocol of the manufacturer.
Results
Nonsupervised analysis differentiated transformed from nontransformed cells. Nonsupervised hierarchical clustering, using 3,242 genes that were filtered on a nonparametric basis as described in Materials and Methods, distinguished perfectly between the enterocytes that had transformed and those that had not (Fig. 1 ). Nonsupervised analysis did not differentiate between cells that were and were not treated with celecoxib, presumably because the normal enterocytes are barely affected by the drug. This result serves as one validation to the quality of the experiment. Supervised analysis revealed a differential gene expression profile in IEC18 cells after Ras transformation or after treatment with celecoxib. A two-way ANOVA test was applied separately for each of the 3,242 genes with two independent variables: transformation (IEC18 versus R1 cells) and status of treatment (no treatment, short treatment of 72 h and long exposure for 6 months that produced resistant cells). There were 538 genes with altered expression between transformed and nontransformed cells. Using correction for multiple comparisons, 52 genes of this group passed false discovery rate correction with cutoff of 0.05 (Table 1 ). Among these, four genes also passed the more strict Bonferroni correction: two are identified by their Genbank codes as AA800711 and S74257 (the latter is a rat gene described in Fos-transformed fibroblasts) and the other two were trangelin and rat cyclin D1. (It should be noted than an important group of genes are those which are affected by transformation and returns to normal after treatment. Obviously, these genes are not represented in this list and will be presented separately later.).
Seventy and 126 genes were differentially expressed in at least 3-fold difference between treated and nontreated cells after short and long exposures to celecoxib, respectively. For 121 genes, the interaction between treatment and transformation status was significant (Table 2) . Among these genes, cyclin D1 had also passed false discovery rate correction for multiple comparisons with a 0.05 criteria.
Although transformation clearly affected cyclin D1 and resulted in overexpression of this gene relative to nontrans formed cell, this effect was blunted by exposure to celecoxib, which resulted in a much lower increase in expression relative to nontreated cell.
Cluster analysis detected genes that change expression after transformation and reverts to normal after treatment with celecoxib. K-means clustering analysis with four predetermined clusters was applied. Of these, three (1, 2, and 4) are characterized by a change in expression after transformation (overexpression or underexpression) that revert to normal after 
NOTE: Data are genes with common name only, numbered according to their original place on the list.
treatment with celecoxib ( Fig. 2A, B, and D) . These genes are essentially what we are looking for while trying to elucidate the preventive mechanism and downstream targets of celecoxib. Cluster 3 describes genes without alteration in expression at all among the six samples (Fig. 2C) . Next, we have done a functional annotation analysis using the annotations of the Gene Ontology database for each of these three clusters separately to detect specific biological pathways that are involved in the mechanism of action of the drug. In Table 3 (A-C), the results for this analysis, done by the EASE software as described, to clusters 1, 2, and 4, respectively, are listed. Two pathways were particularly dominant because the expression of genes that are included in them was changed significantly in all three clusters that differentiate the nontreated R1 cells of all others. The first is of positive or negative regulators of nucleic acid metabolism that results in a positive regulation of transcription in R1 cells. The second is the carbohydrate metabolism pathway: Genes involved in catabolism of hexose and glucose are transcribed more in nontreated R1. Validation of these results confirmed that the Ras pathway is hyperactive in R1 cells; it is also found to be down-regulated by celecoxib (cluster 4). Catabolism of hyaluronic acid is active in R1 cells and is also inhibited by celecoxib.
Overexpression of cyclin D1 prevents the killing effect induced by celecoxib in transformed cells. As a confirmation for our results, we tested the effect of cyclin D1 overexpression in the IEC18 cells under exposure to celecoxib. As cyclin D1 was observed as the gene most affected by celecoxib, it was predicted to be a crucial target gene for its mechanism. IEC18 cells overexpressing cyclin D1 were shown before to posses a malignant phenotype (27) similar to that of the R1 cells. Celecoxib (20 Amol/L) inhibits the growth of the R1 transformed cells by induction of apoptosis (39.6F 3.04%; Fig.  2B ), whereas no effect was observed in the immortalized IEC18 cells, or their cyclin D1 -transformed derivatives (3.5F 1.45% and 3.4F 0.45%, respectively). Furthermore, at higher concentrations of celecoxib, the IEC18 cells were also affected by the drug (9.1F 3.2% at 40 Amol/L and 13.6F 0.7% at 60 Amol/L), whereas the D1 cells were still barely affected (2.9 F 0.4% at 40 Amol/L and 9.4F 1.3% at 60 Amol/L). These results suggest and confirm that down-regulation of cyclin D1 is a significant mechanism by which celecoxib inhibits the growth of cancer cells, without affecting the growth of normal enterocytes.
PGE 2 is oversynthesized in the transformed cells, inhibited by celecoxib. Because COX-2 is overexpressed at cancer cells, we tested the extent to which the classic mechanism of celecoxib, COX-2 inhibition, acts in our cellular model. For that reason, we determined the levels of PGE 2 secreted to the growth medium, the end-product of the cyclooxygenases. Cells after transformation, the R1 cells, showed f16-fold more PGE 2 than cells before transformation, IEC18 (Fig. 2D ). Under treatment with celecoxib, for 72 h, PGE 2 synthesis is reduced to (Fig. 2D) . A very mild effect was seen in IEC18 cells treated with celecoxib. The inhibition was even milder for the cells that had undergone malignant transformation due to overexpression of cyclin D1, which showed little synthesis of PGE 2 to begin with.
Discussion
The main significance of the current study is that it suggests some of the underlying mechanisms that make celecoxib such an effective drug in the prevention of colorectal cancer. It confirms our previous observations that celecoxib selectively inhibits the growth of transformed, but not normal, intestinal epithelial cells.
The main proof lies within the cluster analysis presented (Fig. 3) , where at all the clusters (besides the one that consists of genes that were equally expressed throughout the experiment) no changes were seen after exposures of the normal immortalized cells to the drug, but a reversion toward normal expression was clearly seen while treating the Ras-transformed cells. These results are in alignment with the recent clinical observations, in large clinical trials, that celecoxib can prevent colorectal neoplasia with no side effect. The bioinformatic analysis allows only a limited interpretation of the results. This is mainly because of the small number of samples relative to the number of comparisons that makes a correct statistical hypothesis testing with proper correction for multiple comparisons not entirely applicable; the presented data are thus mainly descriptive. This work is therefore a hypothesis-generating technique as a first step toward a deeper investigation of the discussed chemopreventive agent. However, validation to the results lies within the annotation analysis that among the differentially expressed genes revealed pathways that are interesting for the biologist in the context of the study framework, promising interesting directions for further studies. These results were biologically confirmed in other works by reverse transcription-PCR (21 -24, 33) .
The power of these results is derived out of the validation of the in vitro system of transformation that is in use in this experiment. We showed in former publications that the IEC18 cells went through a successful malignant transformation after transfection with a mutated k-Ras oncogene (21 -24) . In the current study, it is shown in nonsupervised analysis that there are unique gene expression patterns that distinguish the three samples of R1 cells from their comparative normal parental IEC18 cells. A validation of our results was obtained by confirming similar changes in the protein expression of tumorrelated genes such as cyclin D1, COX 2, survivin, and bak (21 -24, 33) .
Using pathway analysis available online, we were able to trace cellular functions that are affected by the transformation and driven back to normal activity after treatment with celecoxib and thus offer alternative pathways by which the drug serves in the prevention of tumor formation. Genes that were included among the three clusters mentioned above are potentially involved in pathways that are related to tumor formation and, hence, are targets for celecoxib. An important pathway that is represented in all three clusters is negative regulation of nucleic acid metabolism. This finding conforms to a conclusion of a former publication of our group that celecoxib reduces cell proliferation rates by inducing a G 2 -M arrest in human colorectal cancer cell lines (33) . A second pathway that seems to be significant is the carbohydrate metabolism, including the genes insulin 1 and insulin 2. We showed that the transformed cells are capable of a higher metabolism that is suppressed by celecoxib. The fact that glucose consumption is elevated in correlation with tumor cell density and activity is also well established, and is the basis for the positron emission tomography scanning methodology (34, 35) .
Furthermore, single genes which activity is normalized after treatment are evident and are suggested to be the alternative target of celecoxib besides affecting prostaglandin synthesis. Especially important as a drug target is cyclin D1, which passed false discovery rate correction under strict criteria for its expression pattern, being overexpressed after transformation and down-regulated by exposure to the drug. Thus, we confirmed the power of our results by overexpressing it in the same IEC18 cell -based system of transformation, and showed that this alone is sufficient to abolish the growth inhibition induced by celecoxib. Cyclin D1 was shown before to be overexpressed in cancer cells harboring a hyperactive Ras pathway, and also to be down-regulated by the nonspecific COX inhibitor sulindac sulfide (12, 23) . Also, cyclin D1 is vastly overexpressed in human colorectal cancer already at an early stage of the carcinogenesis process (32) , which further rationalizes the use of celecoxib in vivo in the setting of colorectal cancer. This result is confirmed by a former study that had shown underexpression of three other cyclins in SW480 human colorectal cancer cells after exposure to sulindac (19) .
Nonetheless, although this study is aimed to search for alternative pathways by which celecoxib affects cancer cells, we were also interested in confirming the level to which the classic mechanism of inhibition of prostaglandin synthesis acts in our model. We showed that transformed cells produce much more PGE 2 than normal cells. Celecoxib inhibits synthesis down to normal-level PGE 2 . This pathway was shown to be nonrelated to those we define in the study, as cyclin D1 -transformed cells do not express a high level of PGE 2 .
Thus, we believe that this study is powered enough to single out other genes as targets of COX-2 inhibitors. Among these are genes that are highly involved in oncogenic signal transduction and were found to be overexpressed in R1, for example, Erk1, a proproliferative kinase of the mitogenactivated protein kinase family, which is also a downstream effector of the Ras pathway; Ral-B expression was interestingly suppressed by celecoxib, and also in a former study (19) , by aspirin, Jagged 2, involved in the Notch signaling pathway for differentiation. Calcineurin binding protein 1 interacts with and inhibits the protein phosphatase calcineurinmediated signal transduction that leads to transcription of genes, among which interleukin-2 and interleukin-8 (36), which were shown to contribute to cancer progression under the Ras pathway (37) . Other genes among these clusters are potentially involved in cell morphology and motility and the relation with the extracellular matrix such as hyaluronidase 2, TYRO3 protein tyrosine kinase 3, and a-tubulin. These data prove that a mutation in oncogene change the protein and behavioral milieu of the cell by cross-talking with many other pathways in which changes are crucial. However, other genes that are not yet known in relation to cancer are proposed by this study to have a potential role in tumorigenesis and chemoprevention, such as lysyl oxidase tyrosine 3-monooxygenase, very low density-lipoprotein receptor, and more. The nuclear factor GADD45a, related to maintenance of genomic stability and DNA repair, was up-regulated at transformation and was also shown in a former study to be downregulated in SW480 colorectal cancer cells after exposure to sulindac (19) . Fig. 3 . A, Western blot analysis confirmed that the clone designated D1overexpresses cyclin D1as against a very weak expression in the normal cells, IEC18, and a vector control, as previously described (28) . B, a scheme of the differential expression of cyclin D1 in the microarray analysis: An elevation in expression is shown after Ras transformation, which is significantly inhibited by short and long treatments with celecoxib. C, IEC18 cells, and their transformed derivative overexpressing cyclin D1 (D1) or k-Ras (R1), were analyzed through fluorescence-activated cell sorting after staining with propidium iodide for their cell cycle properties under 72 h treatments with the indicated concentrations of celecoxib. D, IEC18, D1, and R1were treated with celecoxib for72 h at selected doses. PGE 2 levels in the culture medium were measured by enzyme immunoassay as described. Columns, mean of two experiments; bars, SD.
